Nordic Nanovector announces promising results from preclinical research collaboration to develop novel CD37-targeting alpha therapy for B-cell tumours.
M2 EQUITYBITES-April 2, 2019-Nordic Nanovector announces promising results from preclinical research collaboration to develop novel CD37-targeting alpha therapy for B-cell tumours
(C)2019 M2 COMMUNICATIONS http://www.m2.com
Nordic Nanovector ASA (OSE: NANO), a developer of targeted therapies for haematological cancers, reported on Tuesday that the results from its preclinical research collaboration to develop a novel CD37-targeting alpha therapy for B-cell tumours are promising.
The company said that in June 2016, it established the research collaboration with Orano Med (formerly known as AREVA Med) to develop and investigate a next-generation targeted alpha therapy. This therapy is comprised of Nordic Nanovector's chimeric anti-CD37 antibody (NNV003) and the alpha-particle-generator lead-212 (212Pb) for the treatment of B-cell malignancies.
According to Nordic Nanovector, results from the research describe promising findings from preclinical studies investigating the tolerability and dose-dependent efficacy of 212Pb-NNV003 in mouse models of chronic lymphocytic leukaemia (CLL) and Burkitt's lymphoma (a type of non-Hodgkin's lymphoma, NHL).
These studies found that 212Pb-NNV003 displayed a favourable toxicity profile after a single intravenous injection. In one study, 100% of mice with tumour xenografts were alive five months after the injection of 212Pb-NNV003, while only 50% of control mice receiving cold antibody where alive after 1.5 months.
((Comments on this story may be sent to email@example.com))